glp k 1 GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1 Effectiveness, Mechanisms of Action

Methods This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications

Arzneimittelkommission der deutschen rzteschaft: Aus der UAW-Datenbank: Schwere Immundefekte nach Behandlung mit Rituximab

Side effects tend to be mild and dose-dependent -- injection site reactions, temporary water retention, and mild tingling or flushing

Other serious risks of taking this medicine include gallbladder problems, pancreatitis, diabetic retinopathy complications, hypoglycemia (low blood sugar), allergic reactions, acute kidney injury, and increased heart rate

Some research has been critical of melatonin as a dietary supplement